Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tentative Xeljanz XR Approval Among Several For Zydus Cadila

Final Gilenya Approval Also In The Bag

Executive Summary

Zydus Cadila has clocked up two tentative and four final abbreviated new drug application approvals in a short amount of time, including for Boehringer Ingelheim’s Jentadueto and the discontinued verapamil hydrochloride for injection.

You may also be interested in...

Micro Labs And Zydus Deal Quickly From Tofacitinib Action

Hatch-Waxman cases filed by Pfizer against Micro Labs and Zydus Cadila over generic versions of Pfizer’s Xeljanz/Xeljanz XR will not move to trial, following settlement agreements covering two patents expiring in March 2023 and December 2025.

Sole Challenger HEC Beaten On US Gilenya Patent

Imminent generic competition to Novartis’ Gilenya blockbuster in the US now seems impossible after a US district court held that the company’s dosage-regimen patent was both valid and infringed by HEC’s ANDA product. The Chinese firm may yet appeal the decision.

PTAB rules Gilenya dosing patent is valid

Attempts to bring generics of Novartis’ Gilenya (fingolimod) blockbuster to the US market eight years ahead of schedule have failed for now, with the US Patent Trial and Appeal (PTAB) ruling that a dosing patent shielding the multiple sclerosis drug should stand, rejecting challenges from Apotex, Argentum, Sun Pharma and Teva.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts